Serum level of cryptic tumor antigens in breast cancer patients as determined by two monoclonal antibodies (m85/f36) and its comparison with ca 15-3
✍ Scribed by Dr. T. Ming; Rodric Constantine; Takuma Nemoto
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 563 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
✦ Synopsis
An enzyme immunoassay system that measures cryptic epitopes on breast cancer mucinlike antigens (BCM-EIA) was evaluated in a double-blind manner in sera from 58 normal blood donors, 36 sex-and age-matched controls, 36 patients with benign breast diseases, and 47 patients with breast cancer. Two murine monoclonal antibodies, M85 (IgM) as the solid-phase and F36122 (lgG3) as the probe, were used in the configuration of the assay kit. The assay additionally utilized neuraminidase to remove terminal sialic acid from carbohydrate side-chains to expose cryptic epitopes that were masked in serum specimens. BCM-EIA monoclonal assay from the normal healthy blood donors resulted in 17.34 ? 7.04units/ml(mean ? 1 S.D.)withanupper normal cutoff of 31.4 units/ml. The distributions of serum BCM in the sex-and agematchedcontrols(17.77 ? 11.17)and benign breast diseases (1 4.34 2 1 1.46) were similar to that of normal blood donors. A mean value of 66.04 units/ml and 27.74 unitsiml was obtained from breast cancer patients with active disease and without evidence of dis-ease, respectively, a level much greater than those of normals, controls, and benign breast diseases. Simultaneous analysis of CA 15-3, a putative breast tumor marker, in the normal donors and breast cancer patients revealed correlation regression of (CA 15-3) = 0.876 (BCM) + 1.972, f = 0.856; and (CA respectively. These data showed that there is a statistically significant correlation of CA 15-3 and BCM in normal blood donors' specimens. However, such a strong and positive correlation canot be unequivocally established in breast cancer patients' specimens. In conclusion, the double-blind evaluation of breast cancer patients revealed the feasibility and clinical potential of the assay. The favorable comparison of BCM with CA 15-3 was encouraging. In addition, an excellent repeatability was obtained by 24 different paired and blind specimens supporting the technical reliability of the assay system. These initial results demonstrated that BCM is a potential serum marker parameter for breast cancer.